MitraClip Redux: Mortality Key in COAPT
from MedPage Today
Safety and efficacy were a win-win for the MitraClip device in the COAPT trial of moderate-to-severe, symptomatic mitral regurgitation patients with heart failure who had exhausted pharmaceutical options. Samir Kapadia, MD, an interventional cardiologist in the Cleveland Clinic Department of Cardiovascular Medicine, discusses the significance of the findings and how he sees the path to routine practice.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063